Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Sales and Divestitures (2019)

Historic Gains from Sales and Divestitures for Silence Therapeutics (SLN) over the last 1 years, with Q4 2019 value amounting to $2571.4.

  • Silence Therapeutics' Gains from Sales and Divestitures changed N/A to $2571.4 in Q4 2019 from the same period last year, while for Dec 2019 it was $2571.4, marking a year-over-year change of. This contributed to the annual value of $2553.7 for FY2019, which is N/A changed from last year.
  • Latest data reveals that Silence Therapeutics reported Gains from Sales and Divestitures of $2571.4 as of Q4 2019.
  • Over the past 5 years, Silence Therapeutics' Gains from Sales and Divestitures peaked at $2571.4 during Q4 2019, and registered a low of $1286.3 during Q2 2019.